Enlight-LN™: Registry of US Adult Patients Treated with Lupkynis™ (Voclosporin) for Lupus Nephritis (KIDNEY WEEK 2023) - Oct 15, 2023 - Abstract #INFO16-FR; Pres time: Nov 3, 2023; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Pennsylvania Convention Center; P=N/A | "The Phase 3 AURORA 1 study found that adding voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids led to earlier reductions in proteinuria across biopsy classes, races, and ethnicities, with long-term safety demonstrated over three years in patients who continued treatment in the AURORA 2 study.Here we describe an actively enrolling prospective observational registry, designed to characterize the real-world effectiveness and utilization patterns of voclosporin in the United States.Patients enrolled in Enlight-LN receive standard care in accordance with clinical practice at each site, with no mandatory visits or assessments required by the protocol. Private practices make up 69% of the sites, while the remaining sites are academic centers. Thirty-three sites specialize in rheumatology, twenty-three sites in nephrology, and one site in internal medicine.The study is actively enrolling patients (NCT05337124)."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Rheumatology
|
|
Lily Cipolla1; Victoria Bal1; Henry Leher1
|